Recommended IGF-I dosage causes greater fat accumulation and osseous maturation than lower dosage and may compromise long-term growth effects

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages 839-845

  Guevara Aguirre, Jaime ^a,b   Rosenbloom, Arlan L ^a,b   Guevara Aguirre, Marco ^a   Saavedra, Jannette ^a   Procel, Patricio ^a  

^a Instituto Endocrinologia   (Ecuador)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RECEPTOR; SOMATOMEDIN C;

ABDOMINAL RADIOGRAPHY; ADOLESCENT; ARTICLE; BODY COMPOSITION; BONE AGE; BONE MATURATION; CHILD; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FEMALE; GROWTH HORMONE RECEPTOR GENE; HORMONE RESISTANCE; HUMAN; LIPID STORAGE; MALE; MOLECULAR PATHOLOGY; OBESITY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEPTOR GENE; RECOMMENDED DRUG DOSE;

ADIPOSE TISSUE; ADOLESCENT; BODY HEIGHT; BONE AND BONES; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN-LIKE GROWTH FACTOR I; MALE; TIME;

EID: 84873652298     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3704     Document Type: Article

References (24)

1. Rosenbloom AL. Mecasermin (recombinant human insulin like growth factor-I). Adv Ther. 2009;26:40-54.
2. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Rosenfeld RG. Two year treatment of growth hormone receptordeficiency(GHRD) with recombinant insulin-likegrowthfactor-I in 22 children: comparison of two dosage levels and to GH treated GH deficiency. J Clin Endocrinol Metab. 1997;82:629-633.
3. Wilson KF, Fielder PJ, Guevara-Aguirre J, et al. Long-term effects of insulin-like growth factor (IGF)-I treatment of serum IGFs and IGF binding proteins in adolescent patients with growth hormone receptor deficiency. Clin Endocrinol (Oxf). 1995;42:399-407.
4. Azcona C, Preece MA, Rose SJ, et al. Growth response to rhIGF-I 80 μg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype. Clin Endocrinol (Oxf). 1999;51:787-792.
5. Kržišnik C, Battelino T. Five year treatment with IGF-I of a patient with Laron syndrome in Slovenia (a follow-up report). J Pediatr Endocrinol Metab. 1997;10:443-447.
6. Increlex [package insert]. Banking Ridge, NJ: Ipsen; 2005.
7. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. GH insensitivity syndrome collaborative group. long-term treatment with recombinant IGF-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007;92:902-910.
8. Messina MF, Arrigo T, Valenzise M, et al. Long-term auxological and pubertal outcome of patients with hereditary insulin like growth factor-I deficiency (Laron and growth hormone-gene deletion syndrome) treated with recombinant human insulin like growth factor-I. J Endocrinol Invest. 2011;34:292-295.
9. Guevara-Aguirre J, Vasconez O, Martinez V, et al. A randomized double-blind, placebo-controlled trial of safety and efficacy of recombinant insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab. 1995;80:1393-1398.
10. Martinez V, Vasconez O, Martinez A, et al. Body changes in adolescent patients with growth hormone receptor deficiency receiving recombinant human insulin-like growth factor I and luteinizing hormone-releasing hormone analog: preliminary results. Acta Paediatr Suppl. 1994;399:133-136.
11. Greulich WW, Pyle SI. 1959 Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd ed. Stanford, CA: Stanford University Press.
12. Laron Z. IGF-I treatment of patients with Laron syndrome. In: Laron Z, Kupchik JJ, eds. Laron Syndrome-From Man to Mouse. Berlin, Heidelberg: Springer-Verlag; 2011:343-380.
13. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res. 1999;51:128-134.
14. Vaccarello MA, Diamond FB Jr, Guevara-Aguirre J, et al. Hormonal and metabolic effects and pharmacokinetics of recombinant human insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. J Clin Endocrinol Metab. 1993;77:273-280.
15. Concolino D, Muzzi G, Sestito S, Vega G, Bonapace G, Striscuuglio P. Long-term treatment with recombinant insulin like growth factor 1 (IGF-1) inachildwithIGF-Igenemutation. EurJ Pediatr.2010;169:245-247.
16. Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Pollock BH. Growthin growth hormone insensitivity. Trends Endocrinol Metab. 1994;5:296-303.
17. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331:1056-1061.
18. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80:3689-3698.
19. Sopher AB, Jean AM, Zwany SK, et al. Bone age advancement in prepubertal children with obesity and premature adrenarche: possible potentiating factors. Obesity. 2011;19:1259-1264.
20. Klein KO, Larmore KA, de Lancey E, Brown JM, Considine RV, Hassink SG. Effect of obesity on estradiol level, and its relationship to leptin, bone maturation, and bone mineral density in children. J Clin Endocrinol Metab. 1998;83:3469-3475.
21. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer and diabetes in humans. Sci Transl Med. 2011;3:70ra13.
22. Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N. Long-term IGF-I treatment of children with Laron syndrome increases adiposity. Growth Horm IGF Res. 2006;16:61-64.
23. Tercica says its Increlex provides significant price advantage. The Pharmaletter Web site. http://www.thepharmaletter.com/file/30151/tercica-says- its-increlex-provides-significant-price-advantage. html. Accessed July 25, 2012.
24. Ranke MB, Wolfle J, Schnabel D, Bettendorf M. Treatment of dwarfism with recombinant human insulin like growth factor-1. Dtsch Arztebl Int. 2009;106:703-709.